Back to homepage
MyChart

Clinical Trials

Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies.

Trial #: D3614C00001 CAPItello-290 
Sponsor: AstraZeneca 
Trial Sub-Type: Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) 
Title and Key Inclusion/Exclusion Criteria: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).

Trial #: D3614C00002 CAMBriA-1 
Sponsor: AstraZeneca 
Trial Sub-Type: HR+/HER2- early breast cancer 
Title and Key Inclusion/Exclusion Criteria: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Switching to AZD9833 (a Next Generation, Oral SERD) vs Continuing Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with HR+/HER2- early breast cancer and a intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence (CAMBriA-1)

Trial #: NSABP B-59/ GeparDouze 
Trial Sub-Type: Neoadjuvant Triple-Negative Breast Cancer 
Title and Key Inclusion/Exclusion Criteria: A randomized, double-blind, Phase III clinical trial of Neoadjuvant Chemotherapy with Atezolizumab or placebo in patients with Triple-Negative Breast Cancer followed by adjuvant continuation of Atezolizumab or placebo.

Trial #: NSABP B-60 COMING SOON! 
Trial Sub-Type: Clinically T1-4, N0-3, M0 prior to neoadjuvant therapy (Note: Patients presenting with T1N0 tumors will not be eligible) 
Title and Key Inclusion/Exclusion Criteria: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy.